In advanced prostate cancer, a study identified CDK12 mutant cases associated with elevated neoantigen burden and increased tumor T cell infiltration and summarized that CDK12 inactivation defines a distinct class of metastatic castration-resistant prostate cancer that may benefit from ICI therapy56. The gene discussed is CDK12; the disease is prostate cancer.